Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
thomas.jackson@paediatrics.ox.ac.uk

Research groups

Childhood Leukaemia Research Group

Thomas Jackson

Postdoctoral Research Fellow

Recent publications

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

Ren H. et al, (2026), Blood, 147, 180 - 196

Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease

Ren H. et al, (2025)

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506

The Fetal Specific Gene LIN288 Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Ling RE. et al, (2024), BLOOD, 144, 199 - 200

LIN28B: an important onco-fetal gene in infant acute lymphoblastic leukaemia

Ling R. et al, (2023), HemaSphere, 7

More publications